Joon Lee
Stock Analyst at Truist Financial
(4.97)
# 87
Out of 4,453 analysts
549
Total ratings
59%
Success rate
37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.55 | - | 16 | Mar 17, 2026 | |
| EDIT Editas Medicine | Maintained: Hold | n/a | $2.74 | - | 22 | Mar 17, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $8.86 | - | 11 | Mar 13, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $700 | $327.86 | +113.51% | 29 | Mar 12, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $525 | $480.18 | +9.33% | 16 | Mar 11, 2026 | |
| ANAB AnaptysBio | Maintained: Hold | $50 | $59.68 | -16.22% | 30 | Mar 9, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $36.99 | - | 43 | Mar 5, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | n/a | $57.35 | - | 14 | Mar 3, 2026 | |
| CORT Corcept Therapeutics | Maintained: Buy | n/a | $84.75 | - | 38 | Mar 2, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | n/a | $16.03 | - | 29 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $53.98 | - | 24 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $84.51 | - | 11 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.75 | - | 41 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $52.83 | - | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $31.42 | - | 31 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $226.20 | - | 26 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $237.33 | - | 37 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $76 | $29.25 | +159.83% | 29 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $38.91 | - | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.50 | - | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.21 | - | 24 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $888.65 | - | 38 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $10.41 | n/a | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $7.72 | n/a | 10 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 → $65 | $8.03 | n/a | 5 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 → $4 | $6.45 | n/a | 4 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.17 | n/a | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $11.75 | n/a | 1 | Aug 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $76 | $49.10 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $5.56 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $16.02 | n/a | 1 | Aug 8, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $23.72 | n/a | 1 | Aug 7, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $1.07 | n/a | 1 | Jul 28, 2014 |
Voyager Therapeutics
Mar 17, 2026
Maintained: Buy
Price Target: n/a
Current: $3.55
Upside: -
Editas Medicine
Mar 17, 2026
Maintained: Hold
Price Target: n/a
Current: $2.74
Upside: -
Solid Biosciences
Mar 13, 2026
Maintained: Buy
Price Target: n/a
Current: $8.86
Upside: -
Praxis Precision Medicines
Mar 12, 2026
Reiterated: Buy
Price Target: $700
Current: $327.86
Upside: +113.51%
Vertex Pharmaceuticals
Mar 11, 2026
Maintained: Buy
Price Target: $525
Current: $480.18
Upside: +9.33%
AnaptysBio
Mar 9, 2026
Maintained: Hold
Price Target: $50
Current: $59.68
Upside: -16.22%
Viking Therapeutics
Mar 5, 2026
Maintained: Buy
Price Target: n/a
Current: $36.99
Upside: -
BioMarin Pharmaceutical
Mar 3, 2026
Maintained: Buy
Price Target: n/a
Current: $57.35
Upside: -
Corcept Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $84.75
Upside: -
Intellia Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $16.03
Upside: -
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $53.98
Upside: -
Feb 27, 2026
Maintained: Buy
Price Target: n/a
Current: $84.51
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.75
Upside: -
Feb 26, 2026
Maintained: Buy
Price Target: n/a
Current: $52.83
Upside: -
Feb 26, 2026
Maintained: Buy
Price Target: n/a
Current: $31.42
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $226.20
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: n/a
Current: $237.33
Upside: -
Feb 13, 2026
Maintained: Buy
Price Target: $90 → $76
Current: $29.25
Upside: +159.83%
Nov 10, 2025
Maintained: Buy
Price Target: n/a
Current: $38.91
Upside: -
Nov 6, 2025
Maintained: Buy
Price Target: n/a
Current: $3.50
Upside: -
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $6.21
Upside: -
Aug 1, 2025
Maintained: Buy
Price Target: n/a
Current: $888.65
Upside: -
Dec 4, 2024
Rated: Buy
Price Target: n/a
Current: $10.41
Upside: n/a
Nov 14, 2023
Maintained: Buy
Price Target: $18
Current: $7.72
Upside: n/a
Jan 17, 2023
Maintained: Buy
Price Target: $100 → $65
Current: $8.03
Upside: n/a
Dec 8, 2022
Maintained: Hold
Price Target: $7 → $4
Current: $6.45
Upside: n/a
May 5, 2022
Reiterated: Buy
Price Target: $14
Current: $3.17
Upside: n/a
Aug 8, 2019
Maintained: Buy
Price Target: $10
Current: $11.75
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $76
Current: $49.10
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $20
Current: $5.56
Upside: n/a
Aug 8, 2014
Maintained: Buy
Price Target: n/a
Current: $16.02
Upside: n/a
Aug 7, 2014
Reiterated: Buy
Price Target: $33
Current: $23.72
Upside: n/a
Jul 28, 2014
Maintained: Buy
Price Target: $14
Current: $1.07
Upside: n/a